E-Cigarettes or Medication for Smoking Cessation

Overseen By Tracy Smith, PhD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Medical University of South Carolina

Disqualifiers: Pregnant, Breastfeeding, Moving, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 8

Duration: 11 weeks

225 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine if e-cigarettes are as effective as traditional methods like patches, lozenges, or the medication Chantix (a prescription for smoking cessation) in helping people quit smoking. Researchers will assign participants to one of two groups: one group will try e-cigarettes, selecting from various brands and flavors, while the other group will use either nicotine replacement therapy or Chantix. This trial suits adults who have previously attempted to quit smoking using FDA-approved methods and are interested in reducing smoking-related harms. Participants will engage in weekly phone calls for seven weeks, with a follow-up call at 11 weeks and a visit at six months. As an unphased trial, this study provides a unique opportunity for participants to explore innovative smoking cessation methods and contribute to valuable research.

Do I need to stop my current medications to join the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that e-cigarettes are generally seen as less harmful than regular cigarettes, but they still carry risks. Studies suggest that e-cigarettes can be about as safe as other nicotine replacement options, like patches and lozenges, in the short term. However, their long-term safety remains unclear.

The medications used in the study, varenicline (also known as Chantix) and nicotine replacement therapy (NRT), have undergone extensive research. Varenicline is considered safe and does not show signs of being addictive. It effectively helps people quit smoking. NRT might cause some discomfort but is not linked to serious side effects.

In summary, while e-cigarettes and medications like varenicline and NRT can assist in quitting smoking, it's important to consider their safety and potential risks. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Researchers are excited about these treatments for smoking cessation because they offer personalized choices that cater to different preferences and needs. Unlike traditional options like nicotine patches or gum, the e-cigarette arm allows participants to choose between brands and flavors, which might increase satisfaction and adherence. The medication arm gives participants the flexibility to select between combination nicotine replacement therapy (NRT) with patches and lozenges or varenicline, which targets nicotine receptors in the brain. This tailored approach could enhance the effectiveness and appeal of quitting smoking, potentially leading to higher success rates compared to existing methods.

What evidence suggests that this trial's treatments could be effective for smoking cessation?

This trial will compare the effectiveness of e-cigarettes and medication for smoking cessation. Research has shown that e-cigarettes can aid in quitting smoking. Some studies found that smokers using e-cigarettes were more likely to quit than those who only received counseling. Another study indicated that vaping is a safer option than traditional cigarettes and can assist in smoking cessation.

Meanwhile, medications like varenicline (Chantix) and nicotine replacement therapies (NRT) have also proven effective in helping people quit smoking. Specifically, varenicline has been found to be more effective than NRT. Participants in this trial will be assigned to either the e-cigarette group or the medication group. Each method offers a way to help smokers quit, with both showing success in supporting smoking cessation. ^{6 7 8 9 10}

Who Is on the Research Team?

Tracy Smith

Principal Investigator

[e-mail]

Are You a Good Fit for This Trial?

This trial is for adults over 21 who have tried to quit smoking before using FDA-approved methods and are interested in reducing harm from tobacco or quitting. It's not for those pregnant, breastfeeding, planning pregnancy, living with someone in the study, or moving away soon.

Inclusion Criteria

Interest in reducing harms from tobacco use or quitting smoking

I am over 21 and have tried to quit smoking with FDA-approved medication before.

Exclusion Criteria

Household member currently enrolled in the study

Pregnant, breastfeeding, or trying to become pregnant

Planning to move out of the area within the next 7 months

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants are randomly assigned to either the E-Cigarette Group or the Meds Group and receive study products for 11 weeks

11 weeks

Weekly phone calls for the initial 7 weeks, plus an 11-week phone call

Follow-up

Participants are monitored for safety and effectiveness after treatment

6 months

1 visit (in-person) at 6 months

What Are the Treatments Tested in This Trial?

Interventions

• E-Cigarette
• Medication

Trial Overview

The study compares two ways to quit smoking: one group tries e-cigarettes with a choice of brand and flavor; the other uses medications like nicotine patches/lozenges or Chantix. Participants will be randomly assigned to a group and followed up for 6 months.

How Is the Trial Designed?

Group I: Choice of Medication Experimental Treatment 1 Intervention

This arm includes participants randomly assigned to the Meds Group. Participants will choose between 1) combo NRT and 2) varenicline. The NRT will consist of transdermal NRT and nicotine lozenge. Participants will receive study product for 11 weeks.

Group II: Choice of E-Cigarette Experimental Treatment 1 Intervention

This arm includes participants randomly assigned to the E-Cigarette Group. Participants will choose between two different brands of e-cigarettes and choose up to two different flavors. Participants will receive study product for 11 weeks.

E-Cigarette is already approved in United States, European Union, Canada for the following indications:

Approved in United States as E-Cigarette for:

• Smoking cessation aid

Approved in European Union as E-Cigarette for:

• Smoking cessation aid

Approved in Canada as E-Cigarette for:

• Smoking cessation aid

Who Is Running the Clinical Trial?

Medical University of South Carolina

Lead Sponsor

Trials

994

Recruited

7,408,000+

National Institute on Drug Abuse (NIDA)

Collaborator

Trials

2,658

Recruited

3,409,000+

Published Research Related to This Trial

In a randomized controlled trial, varenicline (Chantix) demonstrated a higher abstinence rate from smoking after one year compared to both bupropion SR (Zyban) and a placebo, indicating its efficacy in treating tobacco dependence.

Despite its effectiveness, varenicline has been associated with serious neuropsychiatric side effects, highlighting the importance of discussing potential risks and benefits with patients considering this treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Treatment of nicotine dependence with Chantix (varenicline). Rankin, KV., Jones, DL.[2015]

Varenicline, a medication used to help people quit smoking, is known to have some psychiatric and behavioral side effects, including reports of tardive dyskinesia, although these were not previously documented in literature.

This study presents the first two documented cases of withdrawal emergent dyskinesias associated with varenicline, highlighting a potential safety concern for users of the medication.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Withdrawal-Emergent Dyskinesias following Varenicline Therapy. Toffey, BA., Rabin, M., Kurlan, R.[2020]

A comprehensive analysis of 8,867,135 reports from the FDA Adverse Event Reporting System revealed that nicotine replacement therapies (NRTs) are associated with several adverse events, including nausea, dizziness, and application site reactions, indicating the need for careful monitoring of their use.

Electronic cigarettes also reported adverse events such as dizziness and increased heart rate, suggesting that while they may be used for smoking cessation, they are not without risks and should be approached with caution.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Adverse events of smoking cessation treatments (nicotine replacement therapy and non-nicotine prescription medication) and electronic cigarettes in the Food and Drug Administration Adverse Event Reporting System, 2004-2016. Motooka, Y., Matsui, T., Slaton, RM., et al.[2022]

Participants who chose varenicline (3,116 individuals) for tobacco cessation had higher abstinence rates at both 3 months (22%) and 6 months (17%) compared to those using nicotine replacement therapy (NRT) (13% at 3 months and 11% at 6 months), indicating that varenicline may be more effective in supporting quitting.

The study found that factors such as increasing age, having health insurance, and the number of counseling sessions were associated with higher rates of abstinence, particularly at 3 months, suggesting that these factors could enhance the effectiveness of quitline services.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Characteristics and abstinence outcomes among tobacco quitline enrollees using varenicline or nicotine replacement therapy. Biazzo, LL., Froshaug, DB., Harwell, TS., et al.[2015]

In a study of 886 adults, e-cigarettes were found to be significantly more effective for smoking cessation than nicotine-replacement products, with a 1-year abstinence rate of 18.0% compared to 9.9% for nicotine-replacement therapy.

Participants using e-cigarettes reported greater declines in cough and phlegm production over the year, although they experienced more throat or mouth irritation compared to those using nicotine-replacement products.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy. Hajek, P., Phillips-Waller, A., Przulj, D., et al.[2022]

In a study involving 140 daily electronic cigarette users, varenicline combined with counseling significantly increased the continuous abstinence rate from vaping compared to a placebo, with rates of 40.0% vs 20.0% during weeks 4-12.

The study also found that varenicline maintained higher rates of vaping abstinence at 34.3% compared to 17.2% at weeks 4-24, indicating its potential effectiveness in vaping cessation programs with minimal serious adverse events.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Varenicline and counseling for vaping cessation: a double-blind, randomized, parallel-group, placebo-controlled trial. Caponnetto, P., Campagna, D., Ahluwalia, JS., et al.[2023]

Smoking cessation is crucial for health, and psychiatric nurses should actively support patients in using therapies like varenicline (Chantix) to quit smoking.

Recent research has raised safety concerns about varenicline, including its potential links to neuropsychiatric side effects, seizures, and interactions with alcohol, which clinicians need to consider when recommending this treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Clinical Psychopharmacology Update: Additional Safety Concerns for Using Varenicline (Chantix) for Smoking Cessation Treatment. Tobin, TJ., Tobin, ML.[2018]

Combination treatments, particularly varenicline with nicotine patches, can lead to higher smoking abstinence rates compared to using varenicline alone, especially in heavy smokers who are more dependent on tobacco.

Overall, combined medications were well tolerated, making them a viable option for hard-core smokers who have struggled to quit with standard therapies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Combinations of pharmacological treatments in smoking cessation. A systematic review]. Underner, M., Perriot, J., Peiffer, G., et al.[2021]

Varenicline has been shown to be more effective than a placebo for smoking cessation in multiple randomized clinical trials, indicating its strong efficacy as a smoking cessation aid.

While electronic cigarettes (ECs) also showed some effectiveness in helping smokers quit, they were not consistently effective across all studies, suggesting that varenicline may be a more reliable option for those looking to stop smoking.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Looking Back and Going Forward: Roles of Varenicline and Electronic Cigarettes in Smoking Cessation. Oloyede, EO., Ola, O., Kolade, VO., et al.[2021]

In a study of over 200,000 adults, varenicline (VAR) was found to have lower smoking-attributable and all-cause medical costs compared to nicotine-replacement therapy patches (NRT-P) over a year, suggesting it may be a more cost-effective smoking cessation option.

Among patients who adhered to their treatment, VAR still showed lower annual medical costs despite higher pharmacy costs, indicating that the overall financial burden of smoking cessation may be reduced with VAR compared to NRT-P.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Healthcare Costs of Smokers Using Varenicline Versus Nicotine-Replacement Therapy Patch in the United States: Evidence from Real-World Practice. Lee, LJ., Li, Q., Bruno, M., et al.[2020]

Nicotine e-cigarettes were found to be more effective for smoking cessation compared to licensed nicotine replacement therapies (NRT), with participants using e-cigarettes being 49% more likely to remain abstinent from smoking than those using NRT.

The review included 7 e-cigarette trials with a total of 5,674 participants and 9 NRT trials with 6,080 participants, but many e-cigarette studies had a moderate to high risk of bias, indicating a need for more rigorous research to confirm these findings.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A systematic review of randomized controlled trials and network meta-analysis of e-cigarettes for smoking cessation. Chan, GCK., Stjepanović, D., Lim, C., et al.[2023]

In a study involving 1251 adult smokers, combining varenicline with a nicotine patch or extending varenicline treatment from 12 to 24 weeks did not significantly improve smoking cessation rates after 52 weeks.

The primary outcome of 7-day point prevalence abstinence was similar across all treatment groups, indicating that neither combination therapy nor longer treatment duration provided additional benefits for quitting smoking.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Effects of Combined Varenicline With Nicotine Patch and of Extended Treatment Duration on Smoking Cessation: A Randomized Clinical Trial. Baker, TB., Piper, ME., Smith, SS., et al.[2022]

Citations

1.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC4752870/

E-cigarettes and smoking cessation in real-world ...

Odds of quitting cigarettes were 28% lower in those who used e-cigarettes compared with those who did not use e-cigarettes (odds ratio [OR] 0·72, 95% CI 0·57–0· ...

2.

nejm.org

nejm.org/doi/full/10.1056/NEJMoa2308815

Electronic Nicotine-Delivery Systems for Smoking Cessation

The addition of e-cigarettes to standard smoking-cessation counseling resulted in greater abstinence from tobacco use among smokers than smoking ...

3.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC10389080/

Use of Vaping as a Smoking Cessation Aid - PubMed Central

Vaping appears to be an effective method for smoking cessation, and it is associated with a lower risk of adverse events than combustible cigarettes.

4.

sciencedirect.com

sciencedirect.com/science/article/pii/S2772963X25002522

The Effect of 12-Week e-Cigarette Use on Smoking ...

Our results showed that even short-term use of e-cigarettes leads to greater smoking cessation at 52 weeks compared to counseling alone. e-Cigarettes are a ...

5.

tobaccocontrol.bmj.com

tobaccocontrol.bmj.com/content/early/2025/02/20/tc-2024-058798

Vaping cessation interventions: a systematic review and ...

Effectiveness of Electronic Cigarettes as a Tool for Smoking Cessation or Reduction. J Pharm Technol 2015;31:8–12. doi:10.1177 ...

6.

cdc.gov

cdc.gov/tobacco/e-cigarettes/health-effects.html

Health Effects of Vaping | Smoking and Tobacco Use

No tobacco products, including e-cigarettes, are safe. Most e-cigarettes contain nicotine, which is highly addictive and is a health danger for ...

7.

lung.org

lung.org/quit-smoking/e-cigarettes-vaping/impact-of-e-cigarettes-on-lung

Health Risks of E-Cigarettes and Vaping

The Food and Drug Administration has not found any e-cigarette to be safe and effective in helping people who use tobacco products to quit. If ...

8.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC6179561/

Safety and Efficacy of Electronic Cigarettes: A Review - PMC

Currently, ECs appear to be as safe as other forms of NRTs and considerably less toxic than cigarette smoking in the short-term. Their long-term safety, however ...

9.

who.int

who.int/news-room/questions-and-answers/item/tobacco-e-cigarettes

Tobacco: E-cigarettes

E-cigarettes as consumer products have not been proven to be effective for cessation at the population level. Instead, alarming evidence on adverse population ...

10.

hopkinsmedicine.org

hopkinsmedicine.org/health/wellness-and-prevention/5-truths-you-need-to-know-about-vaping

5 Vaping Facts You Need to Know

1: Vaping is less harmful than smoking, but it's still not safe. · 2: Research suggests vaping is bad for your heart and lungs. · 3: Electronic cigarettes are ...